Back to search results
NCT07652333

The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication

Recruiting
NAAges 18+InterventionalTreatment
University of Pittsburgh
~40 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Resistance ExerciseGLP-1 RAs

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Body Composition
Measured over From Baseline to Week 12
+1 more outcome measured

Conditions

Muscle Composition
Obesity
Quality of Life (QOL)

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Jiyeon Yoon, M.S. · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Jiyeon Yoon, M.S.
[email protected]
512-817-4601
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Initiating GLP-1 RAs prescribed by physician or advanced practice practitioner and willing to withhold the start of the drug until baseline assessment completed
Non-Smoker
≥18 years old
Obese: Body Mass Index 30-45 kg/m² or BMI ≥27 + ≥1 weight related comorbidity; either hypertension or sleep apnea confirmed by participant self-report
Inactive: not meeting the current US exercise guidelines over the past 6 months
Capable of performing the required exercise training

Exclusion

A serious heart condition, such as unstable heart disease or heart failure, irregular heartbeats that are not well controlled, severe narrowing of the heart valves, or any recent inflammation of the heart or its lining
Cancer requiring treatment in the past 5 years
Hypothyroidism/hyperthyroidism
Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome type 2 (MEN2)
Gastroparesis
Chronic/idiopathic acute pancreatitis
Hepatic disease or cirrhosis
Struggle with alcohol or other substance abuse (heavy drinking (≥4 drinks/day or ≥8 drinks/week for women; ≥5 drinks/day or ≥15 drinks/week for men), or who score ≥3 on the Drug Abuse Screening Test (DAST-10))
Diabetes (Type 1 or 2)
Major risk factors for coronary heart disease such as uncontrolled high blood pressure (≥160 mm Hg systolic or ≥100 mm Hg diastolic)
Problems with your muscles or bones that limit your ability to exercise
Any other medical condition that is life-threatening, can interfere with or be aggravated by the exercise training
Plans to be away ≥2 weeks in the next 3 months
Participation in any other concurrent interventional clinical trial
History of eating disorders or weight-loss surgery, unstable weight (±5% change in past 6 months), or use of obesity medication (e.g., such as Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro) in the last 3 months
Inability to give informed consent
History of major depression or other severe psychiatric disorders (e.g., who answer "yes" to question 9 on PHQ-9 in the Psych\_QoL\_Sleep questionnaires.)
Pregnant or plan to become pregnant during study

What this trial measures

  • Change in Body CompositionFrom Baseline to Week 12

    Dual-energy X-ray absorptiometry (DEXA) will be used to assess fat mass and lean mass. Body fat will be expressed as a percentage of total body composition, and lean mass will be expressed as a percentage of total body composition. Change in each variable will be calculated as the Week 12 value minus the baseline value. Positive values indicate an increase in body fat or lean mass, and negative values indicate a decrease.

  • Change in Quality of LifeFrom Baseline to Week 12

    Quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better quality of life. Change will be calculated as Week 12 minus baseline.